Literature DB >> 29503129

Surgical morbidity and mortality after neoadjuvant chemotherapy in the CRITICS gastric cancer trial.

Y H M Claassen1, H H Hartgrink1, J L Dikken1, W O de Steur1, J W van Sandick2, N C T van Grieken3, A Cats4, A K Trip5, E P M Jansen5, W M Meershoek-Klein Kranenbarg1, J P B M Braak1, H Putter6, M I van Berge Henegouwen7, M Verheij5, C J H van de Velde8.   

Abstract

BACKGROUND: In order to determine the optimal combination of perioperative chemotherapy and chemoradiotherapy for Western patients with advanced resectable gastric cancer, the international multicentre CRITICS trial (ChemoRadiotherapy after Induction chemotherapy In Cancer of the Stomach) was initiated. In this trial, patients with resectable gastric cancer were randomised before start of treatment between adjuvant chemotherapy or adjuvant chemoradiotherapy following neoadjuvant chemotherapy plus gastric cancer resection. The purpose of this study was to report on surgical morbidity and mortality in this trial, and to identify factors associated with surgical morbidity.
METHODS: Patients who underwent a gastrectomy with curative intent were selected. Logistic regression analyses were used to assess risk factors for developing postoperative complications.
RESULTS: Between 2007 and 2015, 788 patients were included in the CRITICS trial, of whom 636 patients were eligible for current analyses. Complications occurred in 296 patients (47%). Postoperative mortality was 2.2% (n = 14). Complications due to anastomotic leakage was cause of death in 5 patients. Failure to complete preoperative chemotherapy (OR = 2.09, P = 0.004), splenectomy (OR = 2.82, P = 0.012), and male sex (OR = 1.55, P = 0.020) were associated with a greater risk for postoperative complications. Total gastrectomy and oesophago-cardia resection were associated with greater risk for morbidity compared with subtotal gastrectomy (OR = 1.88, P = 0.001 and OR = 1.89, P = 0.038).
CONCLUSION: Compared to other Western studies, surgical morbidity in the CRITICS trial was slightly higher whereas mortality was low. Complications following anastomotic leakage was the most important factor for postoperative mortality. Important proxies for developing postoperative complications were failure to complete preoperative chemotherapy, splenectomy, male sex, total gastrectomy, and oesophago-cardia resection.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Gastric cancer surgery; Surgical morbidity; Surgical mortality

Mesh:

Substances:

Year:  2018        PMID: 29503129     DOI: 10.1016/j.ejso.2018.02.004

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  11 in total

1.  Is Sarcopenic Obesity an Indicator of Poor Prognosis in Gastric Cancer Surgery? A Cohort Study in a Western Population.

Authors:  V Rodrigues; F Landi; S Castro; R Mast; N Rodríguez; A Gantxegi; J Pradell; M López-Cano; M Armengol
Journal:  J Gastrointest Surg       Date:  2020-07-13       Impact factor: 3.452

2.  Impact of neoadjuvant therapy followed by laparoscopic radical gastrectomy with D2 lymph node dissection in Western population: A multi-institutional propensity score-matched study.

Authors:  Umberto Bracale; Francesco Corcione; Giusto Pignata; Jacopo Andreuccetti; Pasquale Dolce; Luigi Boni; Elisa Cassinotti; Stefano Olmi; Matteo Uccelli; Monica Gualtierotti; Giovanni Ferrari; Paolo De Martini; Miloš Bjelović; Dragan Gunjić; Diego Cuccurullo; Antonio Sciuto; Felice Pirozzi; Roberto Peltrini
Journal:  J Surg Oncol       Date:  2021-08-25       Impact factor: 2.885

3.  Comparison of short-term and long-term efficacy of laparoscopic and open gastrectomy in high-risk patients with gastric cancer: a propensity score-matching analysis.

Authors:  Bin-Bin Xu; Jun Lu; Zhi-Fang Zheng; Chang-Ming Huang; Chao-Hui Zheng; Jian-Wei Xie; Jia-Bin Wang; Jian-Xian Lin; Qi-Yue Chen; Long-Long Cao; Mi Lin; Ru-Hong Tu; Ze-Ning Huang; Ping Li; Ju-Li Lin
Journal:  Surg Endosc       Date:  2018-06-21       Impact factor: 4.584

4.  Application value of overlap guiding tube (OGT) in assisting overlap esophagojejunostomy during laparoscopic total gastrectomy for gastric/gastroesophageal junction (G/GEJ) tumors.

Authors:  Chen Xinhua; Lin Tian; Huang Huilin; Zhao Mingli; Chen Tao; Chen Hao; Mai Jinsheng; Zhong Qinglei; Liu Hao; Zhao Liying; Hu Yanfeng; Li Guoxin; Yu Jiang
Journal:  Gastric Cancer       Date:  2022-04-23       Impact factor: 7.701

5.  Mixed Type Histology as a Predictive Factor for Esophagojejunostomy Leak in Advanced Gastric Cancer.

Authors:  Karol Rawicz-Pruszyński; Katarzyna Sędłak; Radosław Mlak; Jerzy Mielko; Wojciech P Polkowski
Journal:  Cancers (Basel)       Date:  2020-06-26       Impact factor: 6.639

6.  FLOT Neoadjuvant Chemotherapy Followed by Laparoscopic D2 Gastrectomy in the Treatment of Locally Resectable Advanced Gastric Cancer.

Authors:  Shun Zhang; Dongyi Yan; Qi Sun; Tao Du; Dongliang Cao; Yao Yang; Biao Yuan; Haiqiang Li; Xiaohua Jiang; Chun Song
Journal:  Can J Gastroenterol Hepatol       Date:  2020-05-29

Review 7.  Radiomics in esophageal and gastric cancer.

Authors:  Bert-Ram Sah; Kasia Owczarczyk; Musib Siddique; Gary J R Cook; Vicky Goh
Journal:  Abdom Radiol (NY)       Date:  2019-06

8.  Optimal Timing to Surgery After Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer.

Authors:  Yinkui Wang; Zining Liu; Fei Shan; Xiangji Ying; Yan Zhang; Shuangxi Li; Yongning Jia; Ziyu Li; Jiafu Ji
Journal:  Front Oncol       Date:  2020-12-17       Impact factor: 6.244

9.  Triplet versus doublet neoadjuvant chemotherapy regimens for locally advanced gastric cancer: a propensity score matching analysis.

Authors:  Yonghe Chen; Jiasheng He; Dan Liu; Jian Xiao; Xijie Chen; Haijie Tang; Dandong Luo; Chenyu Shang; Lei Lian; Junsheng Peng
Journal:  BMC Cancer       Date:  2021-12-13       Impact factor: 4.430

10.  Mortality risk factors in patients with gastric cancer using Bayesian and ordinary Lasso logistic models: a study in the Southeast of Iran.

Authors:  Abolfazl Hosseinnataj; Mohammad RezaBaneshi; Abbas Bahrampour
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2020
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.